Biomarkers for tyrosine kinase inhibitors in renal cell cancer

Nicholas Coupe, Michelle Harrison, Wei Chua, Paul de Souza

Research output: Contribution to journalArticlepeer-review

Abstract

Renal cell carcinoma (RCC) is a common malignancy. In 2012, in the USA, there were 65,000 new cases and 13,500 disease-specific deaths. In the same year it was the 6th most common new cancer diagnosed. During the last 50 years, despite an increase in incidence, the mortality has fallen, a possible result of earlier detection and improvements in therapy.
Original languageEnglish
Pages (from-to)216-222
Number of pages7
JournalTranslational Andrology and Urology
Volume1
Issue number4
DOIs
Publication statusPublished - 2012

Open Access - Access Right Statement

Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) https://creativecommons.org/licenses/by-nc-nd/4.0/

Keywords

  • renal cell carcinoma

Fingerprint

Dive into the research topics of 'Biomarkers for tyrosine kinase inhibitors in renal cell cancer'. Together they form a unique fingerprint.

Cite this